Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 168]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Acrivon Therapeutics, Inc. Common Stock - Market capitalization
Acrivon Therapeutics, Inc. Common Stock
ACRV

$217.11 M
Marketcap
$7.01
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

marketcap